echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chuangxiang Biotechnology completes the first patient's first dosing for the global Phase 2 clinical study in the U.S.

    Chuangxiang Biotechnology completes the first patient's first dosing for the global Phase 2 clinical study in the U.S.

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chuangxiang Bio announced that the global phase 2 clinical study ASPIRE, which aims to evaluate the efficacy of izokibep in the treatment of ankylosing spondylitis, completed the first administration of the first patient in California on August 25, Beijing time.
    The patient is currently in good condition
    .

    ASPIRE is a global randomized, double-blind, placebo-controlled Phase 2 clinical study.
    It plans to enroll 300 subjects with active ankylosing spondylitis to evaluate the efficacy and safety of IMG-020
    .
    Chuangxiang Bio will be fully responsible for the global multi-center clinical research, including patient screening, enrollment, treatment and follow-up in the United States, China, South Korea and other countries and Taiwan


    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.